60 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
9 Sep 19
Regulation FD Disclosure
6:50am
injuries (rabbit models) Additionally, positive results from 3 human clinical studies: 2 for Wound Healing and 1 for PE » Demonstrated ability of an eye …
OBG: Timeline to Launch 11 Treating ocular surface pathologies and associated corneal injuries » The initial de novo review for OBG could take up to 9
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
27 May 21
Regulation FD Disclosure
7:01am
– Repositioning as a drug provides access to Medicare Part D reimbursement and flexibility of pricing ~2 million US patients Injuries / abrasions … Surface Wound Healing Market Corneal epithelial and stromal defects are common ocular conditions (2 million annually in the U.S.) – Eye injuries represent
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
14 May 19
EyeGate Pharma Receives Positive Nasdaq Listing Determination
6:55am
injuries including surgical trauma.
EGP-437, EyeGate’s other product in clinical trials, incorporates a reformulated topically active corticosteroid
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Sep 18
EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules
6:58am
, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries including surgical trauma.
EGP
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
12 Dec 18
Regulation FD Disclosure
4:30pm
topical cyclosporine) » Corneal abrasion and alkali burn injuries (rabbit models)
PE (non - dry eye) ~45.0 million Epithelial injury (exposure) ~16.0 … - linking Wounds: Trauma Injuries / Abrasions Chemical burns Difficult to heal (PCED) PE: Dry Eye Episodic / mild Moderate Severe PE: non - Dry Eye Pre
8-K
EX-99.1
yeb4kdmxl9ngq3cof
13 Apr 18
EyeGate Announces $11.25 Million Public Offering
12:00am
8-K
EX-99.1
d6d4ohwzsgpn 60fvw
17 Apr 18
EyeGate Announces Completion of $11.25 Million Public Offering
12:00am
8-K
EX-99.1
1nvxkky 9gf
16 May 18
EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd
4:40pm
8-K
EX-99.1
asyj pi6y04o13w
2 Oct 18
EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care
6:58am
8-K
EX-99.1
500xk4
13 Nov 18
Eyegate Pharma Announces Positive Results In Second PRK Study
7:00am
8-K
EX-99.2
yejz9b c7hv1erppsa63
13 Nov 18
Eyegate Pharma Announces Positive Results In Second PRK Study
7:00am
8-K
EX-99.1
vpswlebgil8xr
11 Jan 22
Regulation FD Disclosure
12:00am
8-K
EX-99.1
ho9jk zqcrd
14 Sep 21
Regulation FD Disclosure
4:20pm
8-K
EX-99.1
vn2gqrede
14 Sep 20
Regulation FD Disclosure
6:50am
424B3
rt0wg k7e
18 Nov 19
Prospectus supplement
4:53pm
424B3
3o3jct
28 Dec 22
Prospectus supplement
4:48pm